Immuron Ltd Owned Ateria Health Launches Juvia in Australia
Immuron Ltd Owned Ateria Health Launches Juvia in Australia
Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that Ateria Health Australia Pty Ltd, a subsidiary of Ateria Health Limited ("Ateria"), has launched Juvia in Australia.
澳大利亞證券交易所股票代碼：IMC、納斯達克代碼：IMRN)今天欣然宣佈，Ateria Health Limited(“Ateria”)的子公司Ateria Health Australia Pty Ltd在澳大利亞推出Juvia。
Immuron completed settlement of a strategic investment in Ateria on 16 November 2022 (17.5% shareholding). Ateria is a UK based biotech company that develops and distributes supplements for overall health, including products that strengthen the gut microbiome.
ImMuron於2022年11月16日完成了對Ateria的戰略投資結算(持股17.5%)。Ateria是一家總部位於英國的生物技術公司，開發和分銷針對整體健康的補充劑，包括增強腸道微生物群的產品。
譯文內容由第三人軟體翻譯。